MaxCyte reports Q2 EPS (10c), consensus (10c)

Reports Q2 revenue $9M, consensus $10.8M. “2023 has been a challenging year across the life sciences industry. An evolving funding environment continues to result in the prioritization of internal pipeline assets by companies, impacting the timing of research and early clinical development projects. Despite this, we remain positive on our ability to successfully deliver on our long-term financial and strategic goals and are encouraged by our continued momentum in signing new clinical partnerships. We believe these partnerships reflect the value of MaxCyte’s premier cell engineering technology and support, underlining the key role we play in enabling a growing set of next-generation cell therapies,” said Doug Doerfler, President and CEO.